TAK-448 is a KISS1R protein agonist as a oligopeptide analog of kisspeptin. In animal model, TAK-448 can stimulate LH/FSH release, whereas continuous sc exposure rapidly down-regulates the pituitary-gonadal axis, with rapid reduction of T levels in a dose-dependent manner. Phase II clinical trials for the treatment of Prostate cancer was discontinued. In Dec 2016, Takeda terminated a phase II trial in Hypogonadism (In adults, In the elderly) in USA because the study did not meet the primary endpoints. Sequence: Ac-Y-Hyp-NTFGLRW-NH2 Source summary: TAK-448 is a peptide compound involved in drug development targeting specific receptors in cancer research.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | Kisspeptin Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.